An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

Research output: Contribution to journalJournal article – Annual report year: 2019Researchpeer-review

Documents

DOI

  • Author: Chu, Dinh-Toi

    Hanoi National University of Education, Viet Nam

  • Author: Duy Bac, Nguyen

    Vietnam Military Medical University, Viet Nam

  • Author: Nguyen, Khanh Hoang

    Research group for Analytical Food Chemistry, National Food Institute, Technical University of Denmark, Kemitorvet, 2800, Kgs. Lyngby, Denmark

  • Author: Le Bao Tien, Nguyen

    Viet Duc Hospital, Viet Nam

  • Author: Van Thanh, Vo

    Viet Duc Hospital, Viet Nam

  • Author: Thi Nga, Vu

    Duy Tan University, Viet Nam

  • Author: Truong Nhu Ngoc, Vo

    Hanoi Medical University, Viet Nam

  • Author: Thi Anh Dao, Duong

    Hanoi National University of Education, Viet Nam

  • Author: Ngoc Hoan, Le

    Hanoi National University of Education, Viet Nam

  • Author: Phuc Hung, Nguyen

    Hanoi National University of Education, Viet Nam

  • Author: Thi Trung Thu, Nguyen

    Hanoi National University of Education, Viet Nam

  • Author: Pham, Van-Huy

    Ton Duc Thang University, Viet Nam

  • Author: Nguyen Vu, Le

    Viet Duc Hospital, Viet Nam

  • Author: Anh Vu Pham, Thuy

    University of Medicine and Pharmacy, Viet Nam

  • Author: B. Thimiri Govinda Raj, Deepak

    Oslo University Hospital, Norway

View graph of relations

The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.
Original languageEnglish
Article number1822
JournalInternational Journal of Molecular Sciences
Volume20
Issue number8
Number of pages17
ISSN1661-6596
DOIs
Publication statusPublished - 2019
CitationsWeb of Science® Times Cited: No match on DOI

    Research areas

  • CD137/4-1BB, CD137L/4-1BBL, anti-CD137 antibodies, cancer immunotherapies, anti-CD137 antibody therapy, Biology (General), QH301-705.5, Chemistry, QD1-999

Download statistics

No data available

ID: 175560693